Sugi Predict

Sugi Predict / Compounds / SCHEMBL488420

SCHEMBL488420

SCHEMBL488420

Nc1ncc(-c2cccc(NS(=O)(=O)CCN3CCN(C(=O)CO)CC3)c2)cc1OCc1c(F)ccc(F)c1Cl

nearest known ligand 0.45

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
▸ MET P08581 14/20 0.45
▸ JAK2 O60674 1/20 0.38
▸ MAP4K3 Q8IVH8 1/20 0.38
▸ MAP4K4 O95819 3/20 0.37
▸ TGFBR1 P36897 2/20 0.35
▸ ACVR1 Q04771 2/20 0.35
▸ BMPR1B O00238 1/20 0.35
▸ BMPR1A P36894 1/20 0.35
▸ ACVRL1 P37023 1/20 0.35
▸ FYN P06241 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30452981 1.00 MET (0.45) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL488191 0.92 MET (0.46) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL30452518 0.92 MET (0.46) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL488386 0.92 MET (0.50) METJAK2MAP4K3MAP4K4
SCHEMBL30453811 0.92 MET (0.50) METJAK2MAP4K3MAP4K4
SCHEMBL30452745 0.90 MET (0.51) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL488343 0.90 MET (0.51) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL488056 0.89 MET (0.51) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL30454528 0.89 MET (0.51) METJAK2MAP4K3MAP4K4TGFBR1
SCHEMBL488348 0.88 MET (0.48) METJAK2MAP4K3MAP4K4TGFBR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-8106197-B2 Aminoheteroaryl compounds as protein kinase inhibitors PFIZER INC. (US) 2012-01-31 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-7230098-B2 2-amino- pyridines and pyrazines additionally substituted witn one or more carbocyclic or heterocyclic groups, e.g., 4-[6-amino-5-(2,6-dichloro-benzyloxy)-pyridin-3-yl]-phenol, for treating many kinds of cancer SUGEN, INC. (US) 2007-06-12 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors SUGEN, INC. 2007-03-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070072874-A1 Aminoheteroaryl compounds as protein kinase inhibitors MET, MAP4K1, MAP4K2 MET 1/4885JAK2 287/4885MAP4K3 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.